secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001193125-25-009573
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst sub-licensee DyDo launches FIRDAPSE in Japan for LEMS
--------------------------------------------------------------

- DyDo Pharma launched FIRDAPSE (amifampridine) 10 mg tablets in Japan for Lambert-Eaton myasthenic syndrome (LEMS).
- FIRDAPSE is the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients 6 years and older.
- Previously approved in U.S., Europe, and Canada; Japan launch expands geographic footprint.
- Catalyst CEO Richard Daly cited commitment to health equity and increasing patient access worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525009573/0001193125-25-009573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525009573/d848918d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-009573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer